Opioid antagonists for pharmacological treatment of alcohol dependence - a critical review
- PMID: 19630726
- DOI: 10.2174/1874473710801030280
Opioid antagonists for pharmacological treatment of alcohol dependence - a critical review
Abstract
Alcohol dependence is a widespread psychiatric disorder. While relapse prevention therapy in alcoholism was exclusively dominated by social and psychological treatments for many years, in the last decades the benefits of pharmacological agents for the rehabilitation treatment in alcoholism have become increasingly evident. Naltrexone, an opiate receptor antagonist, blocks the pleasant and reinforcing effects of alcohol by preventing the stimulation of opioid receptors and the reduction of dopamine release in the ventral tegmental area (VTA). Clinical evidence about the effectiveness of the substance is not always consistent, but meta-analyses confirm naltrexone's effect on the risk of heavy drinking. Evidence about the abstinence-maintaining effects of the substance comes from a relatively small database and needs further investigation. The evaluation of differential effects of naltrexone depending on biological or psychological profiles, which could further enhance the effectiveness of treatments for alcohol dependence, remains a challenge. Nalmefene, another opioid antagonist, as well as naltrexone depot, a sustained release formulation of naltrexone, are further promising strategies for the treatment of alcohol dependence. The review at hand gives on overview of the current evidence on opioid antagonists for the treatment of alcohol dependence regarding the possible mechanism of action, the substances' safety profiles and their effectiveness. The corresponding evidence is critically reviewed taking into consideration the influence of the study design on the magnitude and consistency of effect sizes as well the impact of patient characteristics on the response to the treatment with opioid antagonists. Future studies on the role of different subtypes of alcoholics according to their genetic or psychological profile to explain or even predict the effects of opioid antagonists in the treatment of alcohol dependence are needed.
Similar articles
-
Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review.Addiction. 2004 Jul;99(7):811-28. doi: 10.1111/j.1360-0443.2004.00763.x. Addiction. 2004. PMID: 15200577
-
Pharmacological treatment of alcohol dependence: a review of the evidence.JAMA. 1999 Apr 14;281(14):1318-25. doi: 10.1001/jama.281.14.1318. JAMA. 1999. PMID: 10208148
-
International update: new findings on promising medications.Alcohol Clin Exp Res. 1996 Nov;20(8 Suppl):216A-218A. doi: 10.1111/j.1530-0277.1996.tb01779.x. Alcohol Clin Exp Res. 1996. PMID: 8947268 No abstract available.
-
Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspective.Am J Addict. 2003;12(s1):s69-s80. doi: 10.1111/j.1521-0391.2003.tb00497.x. Am J Addict. 2003. PMID: 14972781 Review.
-
Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes.J Psychopharmacol. 2008 Jan;22(1):11-23. doi: 10.1177/0269881107078308. J Psychopharmacol. 2008. PMID: 18187529
Cited by
-
Chronic alcohol neuroadaptation and stress contribute to susceptibility for alcohol craving and relapse.Pharmacol Ther. 2011 Feb;129(2):149-71. doi: 10.1016/j.pharmthera.2010.09.007. Epub 2010 Oct 15. Pharmacol Ther. 2011. PMID: 20951730 Free PMC article. Review.
-
The monoamine stabilizer (-)-OSU6162 prevents the alcohol deprivation effect and improves motor impulsive behavior in rats.Addict Biol. 2019 May;24(3):471-484. doi: 10.1111/adb.12613. Epub 2018 Feb 26. Addict Biol. 2019. PMID: 29480646 Free PMC article.
-
Chronic alcohol exposure increases ganglia endogenous morphine levels.Arch Med Sci. 2010 Jun 30;6(3):316-20. doi: 10.5114/aoms.2010.14249. Arch Med Sci. 2010. PMID: 22371765 Free PMC article.
-
Naltrexone decreases D-amphetamine and ethanol self-administration in rhesus monkeys.Behav Pharmacol. 2011 Feb;22(1):87-90. doi: 10.1097/FBP.0b013e3283423d55. Behav Pharmacol. 2011. PMID: 21160425 Free PMC article.
-
An amylin analogue attenuates alcohol-related behaviours in various animal models of alcohol use disorder.Neuropsychopharmacology. 2019 May;44(6):1093-1102. doi: 10.1038/s41386-019-0323-x. Epub 2019 Jan 23. Neuropsychopharmacology. 2019. PMID: 30710109 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical